Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Global Cord Blood ( (CORBF) ) is now available.
Global Cord Blood Corporation disclosed that, following a September 22, 2022 order by the Grand Court of the Cayman Islands, joint provisional liquidators from Grant Thornton continue to oversee the company’s affairs. The structure underscores that the group remains under court-supervised provisional liquidation, a status that shapes its governance and limits management’s direct control.
On March 2, 2026, the joint provisional liquidators submitted their fifteenth report to the Cayman court, with the document made available via the company’s investor relations site and a dedicated creditor update page. The steady cadence of reports since October 2022 highlights an ongoing, formal communication channel with creditors and other stakeholders as the wind-down or potential restructuring of the business proceeds under judicial oversight.
More about Global Cord Blood
Global Cord Blood Corporation is a Hong Kong-based provider in the cord blood banking industry, historically focused on collecting, processing and storing umbilical cord blood stem cells. The company operates as a foreign private issuer with its affairs currently overseen by court-appointed joint provisional liquidators in the Cayman Islands, reflecting an ongoing restructuring and insolvency-related process.
Average Trading Volume: 14,942
Technical Sentiment Signal: Hold
Current Market Cap: $127.2M
See more insights into CORBF stock on TipRanks’ Stock Analysis page.